Takeda Pharmaceutical Company Ltd., the largest pharmaceutical company in Japan and an international industry leader, this week announced that it has entered into a purchase agreement to acquire a biologics manufacturing facility located in Brooklyn Park, Minnesota from Baxalta US Inc.
With heavy emphasis placed on research and development, the Osaka-based company that says that it plans to use the Brooklyn Park facility for the manufacture of Entyvio (vedolizumab) and other biologic products. The acquisition will allow Takeda to establish a stronger foothold in the global market and further enhance its product’s supply.
“Takeda’s focus is providing patients access to quality therapies,” Takeda’s Global Manufacturing and Supply Officer Thomas Wozniewski said. “Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.”
Takeda’s recent agreement will enable the company to expand its volume for the production and distribution of other commercial products and clinical trial drugs. Furthermore, the acquisition will allow Takeda to establish and develop direct commercial biomanufacturing expertise.
The financial terms related to the acquisition were not disclosed.